AASLD 2021

The American Association for the Study of Liver Diseases (AASLD) is the leading organization of scientists and health care professionals committed to preventing and curing liver disease.

Please see a daily compilation of the main sessions during which our faculty, fellows, and researchers are presenting at The Liver Meeting Digital Experience, November 12–15, 2021.

Please check back often. Updates will be made as they are received.

AASLD Research Awards

AASLD Foundation Advanced/Transplant Hepatology Award

Karn Wijarnpreecha, MD, MPH
Incidence of cirrhosis and extrahepatic manifestations in lean individuals with nonalcoholic fatty liver disease
Mentor: Anna S. Lok, MD, FAASLD

Leadership Positions

AASLD Committees, Special Interest Groups (SIGs), Journal Editorial Boards

Patricia P. Bloom, MD
Communications and Technology Committee

Trainee Member

Robert Fontana, MD, FAASLD
Hepatology
Editorial Board
Hepatology Communications
Editorial Board

Anna S. Lok, MD, FAASLD
Hepatitis B

Steering Committee
Hepatology
Editorial Board

Jessica L. Mellinger, MD, MSc
Practice Guidelines Committee

Member
Clinical Liver Disease
Associate Editor
Hepatology Communications
Editorial Board
Liver Transplantation
Editorial Board

Neehar D. Parikh, MD, MS
Practice Metrics Committee
Member
Liver Transplantation
Editorial Board

Nataliya Razumilava, MD
Continuing Medical Education Committee
Member

Pratima Sharma, MD, MS
Public Policy Committee
Member
Acute on Chronic Liver Failure
Steering Committee
Liver Transplantation and Surgery
Steering Committee
Liver Transplantation
Associate Editor

Grace L. Su, MD, FAASLD
AASLD 2021 Governing Board

Councilor
AASLD Executive Committee
Clinical Research Committee
Board Liaison
Continuing Medical Education Committee
Board Liaison
Maintenance of Certification Committee
Board Liaison
Membership and Mentorship Committee
Board Liaison

Elliott B. Tapper, MD
Practice Metrics Committee
Chair-Elect
Cirrhosis Quality Collaborative
Hepatology
Editorial Board
Hepatology Communications
Editorial Board
Liver Transplantation
Editorial Board

The Liver Meeting Program - Chairs, Moderators

Saturday, November 13, 2021

Parallel Session 4: COVID-19 Clinical
1:00 pm – 2:30 pm
Moderator: Robert Fontana, MD, FAASLD 

Sunday, November 14, 2021

Late Breaking Session 1
1:00 pm – 2:30 pm
Moderator: Grace L. Su, MD, FAASLD

COVID-19 and the Liver Symposium
7:00 pm – 8:30 pm
Program Chair: Robert Fontana, MD, FAASLD 

Monday, November 15, 2021

Parallel Session 30: Genomics and Precision Medicine
12:30 pm – 2:00 pm
Moderator: Vincent Chen, MD

Invited Speakers

Friday, November 12, 2021

Hepatitis B SIG

11:30 am – 1:00 pm

Novel biomarker – Advances in disease outcome and HBV cure prediction
Anna S. Lok, MD, FAASLD

Public Health / Health Care Delivery SIG

5:30 – 7:00 pm

Behavior management of alcohol-related liver disease (ALD
Jessica L. Mellinger, MD, MSc

Monday, November 15, 2021

Emerging Trends Symposium

10:00 – 11:30 am

NAFLD pathophysiological subtypes: Insights from human genetics
Elizabeth K. Speliotes, MD, PhD, MPH

Pre-Events, Debates, Meet the Experts, Workshops

Pre-event Sessions

Pre-event sessions will launch on Monday, November 8, 2021.

AASLD/ASGE Endoscopy Course

Clinical Challenges and Practical Solutions at the Interface of Liver Disease and Endoscopy

6:00 – 11:25 am

Allison Schulman, MD, MPH

General Hepatology Update

6:00 – 7:30 am

Title of talk TBD
Jessica L. Mellinger, MD, MSc

Value-based Medicine in Hepatology

6:00 – 7:30 am

Title of talk TBD
Elliot B. Tapper, MD

Friday, November 12, 2021

Career Development Workshop

3:00 – 4:30 pm

Elliot B Tapper, MD

AASLD 2021 Academic Debates

7:00 – 8:30 pm

Anuhya Gampa, Matthew Odenwald, Jasleen Singh, Sentia Iriana, Kara Wegermann, Jacqueline Henson, Jason Pan, Abhishek Shenoy

Sunday, November 14, 2021

Basic Research Workshop - Part I (From Liver Phenotype to Gene Discovery)

10:00 – 11:30 am

Elizabeth K. Speliotes, MD, PhD, MPH

Monday, November 15, 2021

Meet the Expert

9:00–10:00 am

Patricia P. Bloom, MD
The role of the microbiome in the pathophysiology of portal hypertension and its complications

Parallel Sessions - Oral Abstract Presentations

Saturday, November 13, 2021

Parallel Session 6: Experimental and Translational Portal Hypertension and ACLF
6:30 – 8:00 pm

Abstract #50
Clustered molecular responses to hyperammonemia mediate sarcopenia in cirrhosis with accelerated skeletal muscle senescence
Nicole Welch, Shashi Shekhar Singh, Avinash Kumar, Saugato Rahman Dhruba, Saurabh Mishra, Jinendiran Sekar, Annette Bellar, Amy Attaway, Aruna Kumar Chelluboyina, Belinda Willard, Ling Li, Zhiguang Huo, Sadashiva S. Karnik, Karyn Esser, Michelle Longworth, Yatrik Shah, Gangarao Davuluri, Ranadip Pal, Srinivasan Dasarathy

Parallel Session 8: HBV cascade of care, natural history and diagnostics
6.30–8.00 pm

Abstract #65
Role of HBV RNA and hepatitis B core-related antigen in predicting sustained inactive carrier phase in chronic hepatitis B
Marc G. Ghany, Wendy C. King, Anna S.F. Lok, Norah Terrault, Harry L.A. Janssen, Raymond T. Chung, Mauricio Lisker-Melman, Amanda S. Hinerman, Mandana Khalili, William M. Lee, Daryl T.Y. Lau, Gavin A. Cloherty, Richard K. Sterling, and the HBRN

Parallel Session 9: COVID-19 Translational and Clinical
6:30 – 8:00 pm

Abstract #71
Long-term clinical outcomes of patients with COVID-19 and chronic liver disease: US multicenter study cold study
Elizabeth Aby, Jenna L Gustafson, Michael Daidone, Raymond T Chung, Sunny Sandhu, Aalam Sohal, Sameeha Khalid, Marina Roytman, Lee Varelas, Akshata Moghe, Ghady Moafa, Nyan L Latt, Rotonya M Carr, Yedidya Saiman, Andreea M Catana, Ihab Kassab, Vincent Chen, Carly Rosenberg, Jose D. Debes, Atoosa Rabiee, Veronica Nguyen, Christina Gainey, Kali Zhou, Kenneth D. Chavin, Blanca Lizaola-Mayo, Sonal Kumar, Renumathy Dhanasekaran

Sunday, November 14, 2021

Parallel Session 11: Healthcare Quality and Access in Hepatology
10:00 – 11:30 am

Abstract #84
The SCAN-ECHO force multiplier effect builds primary care provider capacity through virtual consultations to improve survival for veterans living with liver disease
Ponni V. Perumalswami, Kyle Kumbier, Bradley Youles, Patrick Belancourt, Sameer Saini, Grace L. Su

Parallel Session 19: Clinical Advances in Alcohol-Associated Liver Disease
4:00 – 5:30 pm

Abstract #129
Polygenic risk scores improve identification of individuals at increased risk of alcohol-related liver disease, above alcohol intake alone
Kelly Cushing, Xiaomeng Du, Yanhua Chen, Lc Stetson, Annapurna Kuppa, Elizabeth K. Speliotes

Parallel Session 20: Hepatobiliary Neoplasia: Clinical Oral Session
4:00 – 5:30 pm

Abstract #138
GALAD score improves early detection of HCC prior to the diagnosis of HCC: A phase 3 biomarker validation study
Jorge A. Marrero, Tracey L Marsh, Neehar D. Parikh, Lewis R. Roberts, Myron E Schwartz, Mindie H. Nguyen, Alex Befeler, Stephanie Page-Lester, Jeffrey Winick, Mara Vecchio, Paul Wagner, Sudhir Srivastava, Jo Ann Rinaudo, Amit G. Singal, Ziding Feng, K Rajender Reddy

Monday, November 15, 2021

Parallel Session 27: Diversity, Equity, and Inclusion in Liver Disease Care
10:00 – 11:30 am

Abstract #179
Trends in the inpatient burden of alcohol related liver disease among women hospitalized in the United States
Madeline Bertha, Kerby Shedden, Jessica L. Mellinger

Parallel Session 30: Genomics and Precision Medicine
12:30 – 2:00 pm

Abstract #196
A blood-based prognostic liver secretome signature predictive of long-term HCC risk to guide chemopreventive intervention in advanced liver fibrosis
Naoto Fujiwara, Masahiro Kobayashi, Austin J Fobar, Cesia A Marquez, Bhuvaneswari Koneru, Tongqi Qian, Indu Raman, Quan-Zhen Li, Hitomi Sezaki, Hiromitsu Kumada, Ryosuke Tateishi, Takeshi Yokoo, Adam C Yopp, Raymond T Chung, Bryan C Fuchs, Thomas F. Baumert, Jorge A. Marrero, Neehar D. Parikh, Shijia Zhu, Amit G. Singal, Yujin Hoshida

Posters

Acute Liver Failure and Artificial Liver Support: Acute Liver Failure and Artificial Liver Support

Abstract #248
Outcomes in idiosyncratic drug induced acute liver failure (DILI-ALF) are improving over time
Ashwin Rao, Jody A. Rule, Bilal Hameed, Daniel R. Ganger, Robert J. Fontana, William M. Lee

Alcohol-Associated Liver Diseases: Clinical and Experimental

Abstract #309
Behavior markers in alcohol-related liver disease: Risk perception associates with treatment utilization and abstinence duration
Jessica L. Mellinger, Lara Coughlin, Gerald Winder, Anne Fernandez, Frederic C Blow, Brian Zikmund-Fisher, Anna S. Lok

Biliary Physiology, Transport, Cholangiocyte Biology, Experimental Cholestasis: Cholangiocyte Biology

AASLD Presidential Poster of Distinction
Abstract #421
Extrahepatic bile duct hedgehog signaling regulates CXCL1 recruitment of inflammatory cells to induce proliferation after acute injury
Nureen Hanisah Mohamad Zaki, Junya Shiota, Theresa Keeley, Kazuhiko Nakao, Linda C Samuelson, Nataliya Razumilava

COVID-19 and the Liver - Health Services

AASLD Presidential Poster of Distinction
Abstract #532
Increased alcohol consumption during COVID-19 pandemic is projected to increase alcohol-related  liver disease: A modeling study
Jovan Julien, Turgay Ayer, Carolina Barbosa, William Dowd, Elliot B Tapper, Jag Chhatwal

Genomics and Precision Medicine

Abstract #564
Dietary effects on hepatic steatosis are amplified by genetic risk
Vincent L. Chen, Xiaomeng Du, Yanhua Chen, Annapurna Kuppa, Brian Halligan, Elizabeth K Speliotes

Gut Liver Axis and Microbiome

AASLD Presidential Poster of Distinction
Abstract #594
Microbiota may be linked to increased intestinal permeability in cirrhosis
Patricia Bloom, Shi-Yi Zhou, Christine Bassis, Chung Owyang, Vincent Young, Anna Lok

Health Services and Public Health Research: Health Care Delivery/Access/Quality

Abstract #605
An open access hepatitis C virus case consulting program to expand frontline community provider capacity
Ponni V. Perumalswami, Robert McMorrow, Kaylyn Curtis, Erin Wright, Audrey Hazelbaker, Mary F Myrick, Maureen Mead, Lynsie Stepanski, Dan Oliver, Miranda Jackson, Andrea Daoust, Timothy Shewcraft, Allison Lin, Amy Bohnert, Brandon Harkonen, Sheba Sethi, Anna S. Lok

Abstract #644
Inadequate health literacy is associated with lower rates of hepatocellular carcinoma surveillance in patients with cirrhosis
Kerry Lindquist, Elliot B Tapper, Brooke Wyatt, Amanda Marshall, Pratima Sharma, Alan Wilson, Matoumba M. Claiborne, Marie-Louise Holiday, Andrew W. Tai, Heather McCurdy, Grace L. Su, Ponni V. Perumalswami

Abstract #660
Practical barriers to telehealth visits in hepatology
Chip Bowman-Zamora, Ponni V. Perumalswami, Lon Kai Pang, Patricia Thai, Kaiyi Jiang, Zhuoran Yao, Shawn Fan, Cynthia Chen, Robert Chen, Sabia Abidi, Gary Woods, Costica Aloman, John R Treichler, Andrea D. Branch

Health Services and Public Health Research: Patient Centered Outcomes Research

Abstract #657
Patient portal use is associated with lower 90-day readmissions in decompensated cirrhosis
Jeremy Louissaint, Jeffrey Gibbs, Abhishek Shenoy, Anna S. Lok, Elliot B Tapper

Health Services and Public Health Research: Social Determinants of Health/Disparities/Equity

Abstract #669
Social determinants of health and racial disparities in alcohol treatment utilization for alcohol-related cirrhosis patients
Jessica L. Mellinger, Kerby Shedden

Hepatitis B: Epidemiology, Prevention, Natural History

Abstract #732
Characteristics of older patients with immunotolerant chronic hepatitis B virus infection in the Hepatitis B Research Network (HBRN) adult cohort
Jordan J. Feld, Wendy King, Marc G. Ghany, Kyong-Mi Chang, Norah Terrault, Robert P. Perrillo, Amanda Hinerman, Harry L.A. Janssen, Anna S. Lok, and the Hepatitis B Research Network (HBRN)

Abstract #756
Optimizing hepatitis B virus screening in the United States using a simple demographics-based model
Nathan Ramrakhiani, Vincent Chen, Michael Le, Yee Hui Yeo, Scott D. Barnett, Akbar Waljee, Ji Zhu, Mindie H. Nguyen

Hepatitis B: Therapeutics: Approved Agents

Abstract #783
Effects of HBV subgenotype A2 and an initial 24-week course of peginterferon on outcomes with longer-term tenofovir: The multicenter HBRN Immune Active (IA) trial
Norah Terrault, Anna S. Lok, Abdus Wahed, Marc G. Ghany, Robert P. Perrillo, David Kh Wong, Mandana Khalili, Daryl Lau, Richard K. Sterling, Adrian M Di Bisceglie, Mauricio Lisker-Melman, Stewart Cooper, Raymond T Chung, Keyur Patel, Lewis R. Roberts, Charles Landis, Christopher A. Aoki, Mohamed A. Hassan, Steve Belle, Jay H. Hoofnagle, Harry L.A. Janssen, and the Hepatitis B Research Network

Abstract #811
Symptoms of liver disease during tenofovir therapy with or without peginterferon: Results from the Hepatitis B Research Network Immune Active Trial
Donna M. Evon, Hsing-Hua Lin, Abdus Wahed, Mandana Khalili, Robert J. Fontana, Jay H. Hoofnagle, Hepatitis B Research Network

Abstract #816
The relationship between ALT flares and HBV antigen kinetics during treatment with tenofovir monotherapy or peginterferon plus tenofovir
Robert Perrillo, Anna S Lok, Kelsey Leonard, Marc G. Ghany, Norah Terrault, Steven H. Belle, Harry LA Janssen for the Hepatitis B Research Network

Abstract #817
Treatment withdrawal after long-term nucleotide analogue therapy with or without peginterferon: Predictors of ALT flares, HBsAg decline and active disease
Jordan J. Feld, Abdus Wahed, Marc G. Ghany, Mandana Khalili, Norah Terrault, Robert P. Perrillo, Adrian M Di Bisceglie, Michael W. Fried, Steve Belle, Harry L.A. Janssen, Anna S. Lok, Hepatitis B Research Network (HBRN)

Hepatobiliary Neoplasia: Clinical: Hepatocellular Carcinoma and Cholangiocarcinoma

AASLD Presidential Poster of Distinction
Abstract #1011
Barriers to HCC surveillance in a multicenter US cohort
Neehar D. Parikh, Nabihah Tayob, Taim Al-Jarrah, Jennifer Kramer, Jennifer Melcher, Donna L Smith, Patrick Marquadt, Po-Hong Liu, Nicole E. Rich, Fasiha Kanwal, Amit G. Singal

Abstract #1035
Design and implementation of a best practice advisory in electronic medical records for hepatocellular carcinoma surveillance
Neehar D. Parikh, Cheryl Dehmlow, Tammy Ellies, Anna S. Lok

Abstract #1103
Risk of progression to hepatocellular carcinoma in patients with indeterminate (LI-RADS 3) liver observations
Ashwini Arvind, Sagar Joshi, Timothy Zaki, Daniel A Burkholder, Takeshi Yokoo, David Fetzer, Travis Browning, Nicole E. Rich, Jorge A. Marrero, Adam C Yopp, Purva Gopal, Neehar D. Parikh, Amit G. Singal

Hepatobiliary Neoplasia: Diagnostics and Liver Imaging

Abstract #1169
Multimodal machine learning models combining clinical and quantitative imaging features can predict HCC in indeterminate LI-RADS 3 and 4 lesions in cirrhosis patients
Peng Zhang, Nicholas Wang, Sven Holcombe, Anum Aslam, Neehar D. Parikh, Emily Harding-Theobald, Amit G. Singal, Anna S. Lok, Stewart Wang, Issac R Francis, Grace L. Su

Abstract #1170
Natural history of sub-centimeter liver lesions on abdominal ultrasound
Samuel Phen, Jonathan Melendez-Torres, Nicole E. Rich, Sruthi Yekkaluri, Travis Browning, David Fetzer, Takeshi, Yokoo, Neehar D. Parikh, Amit G. Singal

Hepatotoxicity: Drug Metabolism, Toxicity, and Therapeutics

Abstract #1199
Characteristics of liver injury in antiepileptic drugs (AEDs) in the United States: Results from the DILIN Prospective Study
Naga P. Chalasani, Jonathan G Stine, Herbert L Bonkovsky, Huiman Barnhart, David E Kleiner, Robert J. Fontana, Jay H. Hoofnagle

Abstract #1215
Methylprednisolone associated drug-induced liver injury
Jawad Ahmad, Yi-Ju Li, Huiman Barnhart, Elizabeth J. Phillips, Paul H. Hayashi, Naga P. Chalasani, Robert J. Fontana, David E Kleiner, Jay H. Hoofnagle

Abstract #1234
Vancomycin induced liver injury, DRESS, and HLA-A*32:01
Bilal Asif, Christopher Koh, Huiman Barnhart, Naga P. Chalasani, Robert J. Fontana, Paul H. Hayashi, Victor J. Navarro, Elizabeth J. Phillips, Jay H. Hoofnagle, and the Drug Induced Liver Injury Network

Hepatotoxicity - Predictors of Drug Toxicity

Abstract #1200
Clinical features of sulfonamide hepatotoxicity significantly vary by patient age: Results from the DILIN Prospective Study
Robert J. Fontana, Naga P. Chalasani, Jiezhun Gu, David E Kleiner, Herbert L Bonkovsky, Huiman Barnhart, Jay H. Hoofnagle

Abstract #1214
Liver injury in patients receiving durvalumab is associated with increased mortality but infrequently attributed to the drug
Ihab A Kassab, Linnea Swanson, Irene Tsung, Robert J. Fontana

Abstract #1225
Secular trends in the etiologies and outcomes of patients with idiosyncratic DILI in the United States: Results from the DILIN Prospective Study
Robert J. Fontana, Huiman Barnhart, Naga Chalasani, Paul Watkins, David Kleiner, Joe Odin, Andrew Stolz, Victor Navarro, Jose Serrano, Sherry Gu, Jay Hoofnagle

Abstract #1230
The role of chemical analysis in causality assessment of herbal and dietary supplement (HDS) induced liver injury
Ashley Davis, Victor J. Navarro, Jawad Ahmad, Bharathi Avula, Huiman Barnhart, A. Sidney Barritt IV, Herbert L Bonkovsky, Vincent Chen, Gina Choi, Robert J. Fontana, Marwan S. Ghabril, Paul H. Hayashi, Ikhlas Khan, Christopher Koh, Joseph Odin, Don C. Rockey, Simona Rossi, Hoss Rostami, Leonard B. Seeff, Jose Serrano, Averell H. Sherker, Andrew Stolz, Hans L. Tillmann, Raj Vuppalanchi

Liver Transplantation and Liver Surgery: Donor And Allocation Issues, Living Donor and Split Liver Transplantation, and Hepatobiliary Surgery

Abstract #1430
Impact of new simultaneous liver kidney allocation policy on post liver transplant outcomes and number of kidneys used
Muhammad Waleed, Muhammad Hassaan Arif Maan, Yong-Fang Kuo, Paul Yien Kwo, Nadim Mahmud, Pratima Sharma, Mitra K. Nadim, Ashwani K. Singal

Liver Transplantation and Liver Surgery: Immunosuppression, Outcomes, and Complications

Abstract #1470
Cardiac positron emission tomography myocardial perfusion imaging (PET MPI) findings predictive of post-transplant major adverse cardiac events
Dempsey L. Hughes, Adeline Answine, Kirby Shedden, Monica A. Tincopa, Christopher J. Sonnenday, Sathish Kumar, Robert J. Fontana, Pratima Sharma

NAFLD and NASH: Epidemiology and Natural History, Prevention and Outcomes

AASLD Presidential Poster of Distinction
Abstract #1693
Heterogeneity in risk for advanced disease among NAFLD patients across the age spectrum
Matthew J Miller, Emily Harding-Theobald, Jacob V DiBattista, Daniel Burkholder, Vincent Chen

Abstract #1710
Metabolic abnormalities, liver and body fat in American versus Chinese patients with non-alcoholic fatty liver disease
Wei Zhang, Grace L. Su, Sravanthi Kaza, Rui Huang, Yi Wang, Huiying Rao, Lai Wei, Anna S. Lok

AASLD Presidential Poster of Distinction
Abstract #1724
Prevalence of high liver stiffness and a screening strategy via SODA-2B score among US adults
Sebastian Niezen, Elliot B Tapper, Hirsh Trivedi, Michelle Lai, Michael P. Curry, Kenneth Mukamal, Z. Gordon Jiang

Abstract #1734
Severe hepatic steatosis by controlled attenuation parameter predicts patient-reported outcomes independent of fibrosis
Hirsh Trivedi, Sebastian Niezen, Z. Gordon Jiang, Elliot B Tapper

Abstract #1754
Weight gain and nonalcoholic fatty liver disease and fibrosis detected by fibroscan in the United States
Karn Wijarnpreecha, Elizabeth Aby, Aijaz Ahmed, Donghee Kim

NAFLD and NASH: Experimental: Basic

AASLD Presidential Poster of Distinction
Abstract #1809
MTTP is associated with imaging measured nonalcoholic fatty liver disease in population based and biobank cohorts
Xiaomeng Du, Lc Stetson, Yanhua Chen, Annapurna Kuppa, Elizabeth K. Speliotes, GOLD Consortium

Abstract #1815
Perturbation of TM6SF2 alters hepatic lipid metabolism and lipid species composition
Asmita Pant, Yue Chen, Annapurna Kuppa, Xiaomeng Du, Brian D Halligan, Elizabeth K. Speliotes

Abstract #1834
The LMNA R644C variant is associated with hepatic steatosis in a large cohort and increases lipid accumulation in human hepatoma cells
Kapil Upadhyay, Xiaomeng Du, Yanhua Chen, Lc Stetson, M Bishr Omary, Elizabeth K. Speliotes, Graham Brady

Portal Hypertension and Other Complications of Cirrhosis: Ascites, Renal Dysfunction, and Hepatorenal Syndrome

Abstract #2006
Medication records, not diagnosis codes, are the optimal method to identify ascites using administrative data: A multicenter study
Jennifer Dziwis, Juan Gonzalez, Elliot B Tapper, Yuval Patel

Portal Hypertension and Other Complications of Cirrhosis: Encephalopathy, Infections, and Other Complications

Abstract #2039
Effect of fecal microbiota transplant on hepatic encephalopathy varies by donor and recipient factors
Patricia Bloom, John Donlan, Mariam Torres Soto, Michael Daidone, Elizabeth Hohmann, Raymond T Chung

Abstract #2066
Post-TIPS evolution of the echocardiographic markers of cirrhotic cardiomyopathy
John Laurenzano, Claire Harrington, Nikhilesh Mazumder, Jing Gao, Deepak Gupta, Anthony Borgmann, Lisa Van Wagner, Manhal Izzy, Justin Richard Boike

Vascular Liver Disease, Hemostasis and Thrombosis: Hemostasis and Thrombosis

Abstract #2150
Prophylactic use of blood products prior to paracentesis and thoracentesis among patients hospitalized with decompensated cirrhosis is related to provider specialty and not risk of bleeding or bleeding complications
Abhishek Shenoy, Elliot B Tapper, Anna S. Lok